Advancing AIDSVAX(TM) to phase 3. Safety, immunogenicity, and plans for phase 3

AIDS Research and Human Retroviruses

Volumn 14, Issue SUPPL. 3, 1998, Pages

  Francis, D P ^a   Gregory, T ^a   McElrath, M J ^a   Belshe, R B ^a   Gorse, G J ^a   Migasena, S ^a   Kitayaporn, D ^a   Pitisuttitham, P ^a   Matthews, T ^a   Schwartz, D H ^a   Berman, P W ^a  

^a VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PURIFICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; VACCINE PRODUCTION; BIOSYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFANT;

ADULT; AIDS VACCINES; CLINICAL TRIALS, PHASE III; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFANT; MALE;

EID: 0031763443     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)